



Published in final edited form as:

*J Cereb Blood Flow Metab.* 2008 October ; 28(10): 1754–1760. doi:10.1038/jcbfm.2008.63.

## Cerebral mitochondrial metabolism in early Parkinson Disease

William J. Powers, MD<sup>1</sup>, Tom O. Videen, PhD<sup>2</sup>, Joanne Markham, MS<sup>3</sup>, Kevin J. Black, MD<sup>4</sup>, Nima Golchin<sup>5</sup>, and Joel S. Perlmutter, MD<sup>6</sup>

<sup>1</sup>Department of Neurology, University of North Carolina-Chapel Hill

<sup>2</sup>Departments of Neurology, and the Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO

<sup>3</sup>Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO

<sup>4</sup>Department of Psychiatry and the Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO

<sup>5</sup>Department of Neurology, Washington University School of Medicine, St. Louis, MO

<sup>6</sup>Departments of Neurology, Anatomy and Neurobiology, the Program in Physical Therapy and the Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO

### Abstract

Abnormal cerebral energy metabolism due to dysfunction of mitochondrial electron transport has been implicated in the pathogenesis of Parkinson Disease (PD). However, in vivo data of mitochondrial dysfunction has been inconsistent. We directly investigated mitochondrial oxidative metabolism in vivo in 12 patients with early, never-medicated PD and 12 age-matched normal controls by combined measurements of the cerebral metabolic rate of oxygen (CMRO<sub>2</sub>) and the cerebral metabolic rate of glucose (CMRglc) with positron emission tomography. The primary analysis showed a statistically significant 24% increase in bihemispheric CMRO<sub>2</sub> and no change in CMRO<sub>2</sub>/CMRglc. These findings are inconsistent with a defect in mitochondrial oxidative phosphorylation due to reduced activity of the mitochondrial ETS. Since PD symptoms were already manifest, deficient energy production due to a reduced activity of the mitochondrial ETS cannot be a primary mechanism of neuronal death in early PD. Alternatively, this general increase in CMRO<sub>2</sub> could be due, not to increased metabolic demand, but to an uncoupling of ATP production from oxidation in the terminal stage of oxidative phosphorylation. Whether this is the case in early PD and whether or not it is important in the pathogenesis of PD will require further study.

### Keywords

Parkinson Disease; Cerebral oxygen metabolism; Cerebral glucose metabolism; Positron emission tomography; Mitochondrial

## INTRODUCTION

Parkinson disease (PD) is a degenerative neurological disease that is manifested by tremor, rigidity, bradykinesia and postural instability (Calne et al, 1992). Although PD is characterized

---

Corresponding Author: William J. Powers, MD, Department of Neurology, 3114 Bioinformatics Bldg, CB #7025, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7025, Telephone: 919 966-8178, e-mail: powersw@neurology.unc.edu.

DISCLOSURE/CONFLICT OF INTEREST

The authors have no conflicts of interest.

neuropathologically by alpha-synuclein-immunopositive Lewy bodies in the substantia nigra and other brainstem structures, there is an increasing recognition that PD is a diffuse brain disease involving both cortical and subcortical structures (Braak et al, 2003). Dysfunction of mitochondrial oxidative metabolism has been implicated in the pathogenesis of PD through a variety of mechanisms including reduced ATP production and generation of free radicals (Abou-Sleiman et al, 2006). Diminished activity in complex I of the mitochondrial electron transport system (ETS) in post-mortem brain tissue has been reported in cortex and substantia nigra as well as in platelets (Krige et al, 1992; Schapira 1994; Keeney et al, 2006). In vivo evidence of mitochondrial electron transport dysfunction has been inconsistent. Low ATP levels have been reported in the cortex in two studies (Piert et al, 1996; Rango et al, 2006). Overall cerebral oxygen metabolism has been reported to be not different from normal, but with relative increases in the basal ganglia opposite to the most symptomatic side (Wolfson et al, 1985; Leenders et al, 1985). These in vivo studies were performed in patients with mean disease duration of 6–7 years that was clinically advanced enough to have required treatment with L-dopa. If a defect in mitochondrial electron transport is important in the pathogenesis of PD, it will be present early in the course of the disease and prior to the possibly confounding effects of drug therapy.

Dysfunction of the mitochondrial ETS will reduce the cerebral metabolic rate of oxygen (CMRO<sub>2</sub>). However, since the brain regulates metabolism to match energy demand, both CMRO<sub>2</sub> and the cerebral metabolic rate of glucose (CMRglc) are reduced under any condition with diminished energy demand, such as barbiturate anesthesia (Astrup et al, 1981). Specific defects in mitochondrial ETS decrease CMRO<sub>2</sub> proportionately more than CMRglc (fewer moles of oxygen consumed per mole of glucose metabolized), thereby producing a reduction in the CMRO<sub>2</sub>/CMRglc ratio below the normal value of 5.6 (Brierley et al, 1977; Frackowiak et al, 1988). (This is in distinction to the situation during physiological brain activation in which the CMRO<sub>2</sub>/CMRglc ratio is also below normal, but CMRO<sub>2</sub> is not reduced (Dienel et al, 2002).) Therefore, in vivo assessment of mitochondrial energy metabolism requires combined measurement of CMRO<sub>2</sub> and CMRglc, which has not previously been performed in Parkinson Disease (Frackowiak et al, 1988). To assess the role of defects in mitochondrial metabolism in the pathogenesis of PD, we directly measured CMRO<sub>2</sub> and CMRglc in vivo with positron emission tomography (PET) in early, never-medicated participants with PD and compared to age-matched normal controls.

## MATERIALS AND METHODS

### Participants

**Parkinson Disease**—Participants with PD were recruited from the Washington University Movement Disorders Center.

Inclusion criteria were:

1. Clinically definite PD:
  - a. onset after age 30 years.
  - b. Three of the following: rest tremor, rigidity, bradykinesia or postural instability; or two of these features with one of the first three displaying asymmetry (Calne et al, 1992).
  - c. Three or more of the following: unilateral onset; persistent asymmetry; rest tremor; or progression (United Kingdom Parkinson Disease Society Brain Bank criteria) (Hughes et al, 1992)
  - d. Asymmetric resting tremor (Rajput et al, 1991)

2. Symptomatic for less than 4 years
3. Never taken any anti-parkinsonian medication.

Exclusion criteria were:

1. Any of the following: a history of stroke; history of head injury; history of definite encephalitis, oculogyric crises; previous dopamine receptor antagonist treatment; sustained remission; strictly unilateral features after 3 years; supranuclear gaze palsy; cerebellar signs; early severe autonomic involvement; early severe dementia (within first year of onset) with disturbances of memory, language, and praxis; extensor plantar reflex; any defect on brain imaging; or MPTP exposure.
2. Major neurological or psychiatric disease other than PD or clinically significant lesions on brain imaging that was done prior to enrollment in the study.
3. Regular treatment or exposure in the last 6 months to flunarizine, cinnarizine, reserpine, amphetamines, MAO inhibitors or other medications that might interfere with mitochondrial metabolism.
4. Currently taking chloramphenicol or valproic acid
5. Ever having taken dopaminergic medications for any reason
6. Anticholinergics, amantadine, CoQ10, selegiline and Vitamins E and C must be discontinued for 30 days prior to entry into the study
7. Diabetes mellitus treated by medications
8. Pregnancy

All underwent clinical neurological evaluation by Movement Disorder specialists and were assigned a duration of symptoms and a clinically more involved side of the body based on this examination. They were all followed clinically for at least three years to determine whether each still met the above clinical criteria for idiopathic PD. This determination was made by an investigator blind to the PET data.

**Normal controls**—Normal controls were recruited contemporaneously by public advertisement and from friends and spouses of patients. All underwent clinical neurological evaluation by a neurologist.

Inclusion criteria were:

1. Disease free by subject's own history including no history of migraine, childhood febrile seizures or head trauma with loss of consciousness
2. Taking no medication by subject's own history
3. No signs or symptoms of neurological disease other than mild distal sensory loss in the legs consistent with age
4. No pathological lesions on MR scan done for this study (see below). Mild atrophy and punctate asymptomatic white matter abnormalities were not considered pathological. Exclusion criteria were the same as for the participants with PD.

Normal controls were recruited as part of a larger study including patients with Huntington's Disease and then retrospectively age matched to the patients with Parkinson Disease without reference to PET measurements (Powers et al, 2007).

## Image Acquisition

T1-weighted MR images were acquired with a Siemens Sonata 1.5T scanner (Siemens Medical Solutions USA, Inc., Malvern, PA). A mid-sagittal scout spin-echo sequence was used to position the subject, then a 3-D MPRAGE sequence was acquired (TR/TE/TI=1900/3.93/1100 ms, FA=8°, 7:07 min, 128×256×256 matrix 1.25×1×1 mm voxels). In 10 patients and 11 controls high-resolution MR images were acquired with a Siemens Allegra 3T scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) to permit identification of the substantia nigra. A 2-D turbo spin echo sequence (TR/TE=5540/99 ms, FA=180°, 384×512 matrix 0.5×0.5×2 mm voxels acquired as 21 interleaved, contiguous planes) was co-registered to an MPRAGE image, which, in turn, was co-registered to the MPRAGE image from the 1.5T scanner.

PET images were obtained in the 2-D acquisition mode with a Siemens/CTI ECAT EXACT HR 47 PET scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) with participants lying supine in a quiet dark room. Cerebral blood flow (CBF), cerebral blood volume (CBV), CMRO<sub>2</sub> and oxygen extraction fraction (OEF) were measured as previously described (Raichle et al, 1983; Mintun et al, 1984; Martin et al, 1987; Powers et al, 2007). Arterial blood samples for measurement of pCO<sub>2</sub> and oxygen content were collected and analyzed (Instrumentation Laboratory, Lexington, MA). In one PD participant and one control pCO<sub>2</sub> measurement were not done because of a broken machine. Dynamic emission PET scans were obtained after slow intravenous injection over 10–20 seconds of 10 mCi of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>FDG) for measurement of CMRglc (Powers et al, 2007). All PET emission scans were reconstructed with filtered back projection using the individual attenuation measurements and scatter correction with a ramp filter cutoff at the Nyquist frequency producing images with a resolution of 4.3 mm full width at half maximum.

## Image Analysis

The 1.5 T MR image was segmented into brain and cerebrospinal fluid (CSF) based on voxel intensities. Manual editing was required to remove external tissue where there was insufficient CSF to separate the brain (near sinuses, temporal lobes, eyes, and brainstem), and a single erosion followed by conditional dilation completed the tissue segmentation. The MR image was then edited manually to generate a region of interest encompassing both cerebral hemispheres by removing the cerebellum and brainstem along a plane connecting the posterior commissure and the most inferior point of the interpeduncular fossa.

The substantia nigra was identified on the 3T turbo spin echo sequence (Foster et al, 2007). This region included both the pars compacta and the pars reticulata. Although the pars compacta is the primary site of pathology in PD, the spatial resolution of PET limits the small size of the region from which metabolic measures can be made and components of the pars compacta extend finger-like projections into pars reticulata making anatomic separation of the two not feasible on MRI (Damier et al, 1999).

The putamen was identified on the 1.5T MPRAGE sequences. Medially and anteriorly, the putamen was defined on the coronal view. Where separation from caudate or nucleus accumbens by white matter was not clear, an arbitrary straight line was drawn laterally and inferiorly following the direction of the internal capsule on this section. This rule does not correspond perfectly to anatomic putamen, but represents a necessary compromise, since histologic detail is required to distinguish putamen from caudate or nucleus accumbens accurately. Laterally the claustrum was excluded whenever the external capsule could be partially or completely visualized. The tail of the caudate was excluded by reference to sagittal views.

The globus pallidus was identified on 1.5T transverse MPRAGE images by its lateral border with the putamen and its medial border with the internal capsule. The highest and lowest MRI images that contained visible pallidum nestled against putamen defined its superior and inferior borders.

The volume of the substantia nigra, putamen and globus pallidus for each participant were determined from the number of voxels within each structure and the voxel volume size.

The original segmented MR image plus the three  $^{15}\text{O}$  PET images were co-registered to a composite 40–60 minute  $^{18}\text{F}$ FDG PET image using Automated Image Registration software (AIR, Roger Woods, University of California, Los Angeles, CA) (Woods et al, 1993). Mean counts corrected for partial volume effects due to non-brain structures including CSF were generated for the bihemispheric, substantia nigra, putamen and globus pallidus regions of interest for each of the three  $^{15}\text{O}$  PET images and for the dynamic  $^{18}\text{F}$ FDG PET images (Videen et al, 1999; Powers et al, 2007). Corrected mean counts were converted to quantitative CBF, OEF or CMRO2 (Videen et al, 1987).

For measurement of bihemispheric CMRglc, a modified Marquardt parameter estimation routine was used to derive rate constants for each participant using the partial volume corrected dynamic bihemispheric  $^{18}\text{F}$ FDG PET counts and arterial whole blood time-radioactivity curves (Powers et al, 2007). For calculation of regional substantia nigra, putamen and globus pallidus CMRglc, we employed a single scan strategy utilizing mean  $^{18}\text{F}$ FDG counts integrated from 40–60 min post-injection and a single set of rate constants (Phelps et al, 1979). We compared the 4 rate constants derived from bihemispheric parameter estimation in the 12 participants with PD and the 12 age-matched normal controls (see below) and found no difference (all  $p > .3$ ). We therefore used the mean values for the rate constants derived from all 24 participants in the calculation of regional CMRglc. For this study, we calculated from our entire series of 23 normal control subjects ages 26–70 a value for the lumped constant of 0.64 that yielded a mean bihemispheric value for CMRO2/CMRglc equal to the value of 5.6 that has been directly measured from arterial and jugular venous samples in normal adults, ages 21–69 (Gottstein et al, 1963).

### Statistical Analysis

The null hypothesis of no difference in cerebral oxygen metabolism in patients with early PD was tested by comparison of bihemispheric CMRO2 between participants with PD and age-matched normal controls by 2-sided unpaired t-test with the criterion for statistical significance set at  $p < .05$  (SPSS 15.0 for Windows, SPSS, Inc.) To further understand the pathophysiology of the changes in CMRO2, we performed secondary explanatory analyses of bihemispheric CMRO2/CMRglc and CMRglc. In addition we analyzed regional CMRO2, CMRO2/CMRglc and CMRglc from bilateral substantia nigra, putamen and globus pallidus. For substantia nigra, these data were only available for 10 controls and 10 participants with PD. Two participants with PD and one control did not undergo 3T MR scanning due to machine unavailability. In one additional control subject, CMRO2 measurements were unreliable due to low counts (calculated CMRO2 was negative). We also analyzed regional/hemispheric ratios of CMRO2 and CMRglc in the putamen and globus pallidus to determine if changes were a reflection of overall bihemispheric changes or were specific to these structures. All of these analyses were performed by unpaired t-tests. Finally, we determined if there were asymmetries in CMRO2 and CMRglc in the putamen and globus pallidus based on the side of the body with the most prominent parkinsonian signs (paired t-test). These data, along with measurements of systemic physiology and bihemispheric PET and MR measurements, are presented with p-values from 2-sided t-tests that are uncorrected for multiple comparisons. Data are presented as mean  $\pm$  SD, unless otherwise noted.

This protocol received prior approval by the Washington University Human Studies Committee (IRB). Written informed consent was obtained from all participants.

## RESULTS

### Participants

Twenty-two subjects with PD were initially enrolled. Complete studies were carried out in 12. Eight did not have complete PET and MR studies due to technical problems. Two were determined not to have PD by lack of persisting asymmetry and no motor response to high doses of levodopa. The 12 participants with PD were ages 44–77 (mean 60). There were 6 men and 6 women. Symptom duration was 8–48 months (mean 22). Hoehn and Yahr stages were: 2 Stage 1, 1 Stage 1.5, and 9 Stage 2 (Hoehn and Yahr 1967). Thirty-three normal control subjects were initially enrolled in the combined study of PD and Huntington's Disease. Ten did not successfully complete PET and MR studies: eight due to technical problems, one had an abnormal MR scan and one withdrew after MR. From the 23 who successfully completed PET and MR studies, 12 were matched by age to the 12 participants with PD without reference to any PET or MR data. Their ages were 45–71 (mean 61) years. There were 6 men and 6 women. Exclusion of subjects for incorrect diagnosis of PD and for technical reasons was independent of diagnosis and performed prior to any group data analysis.

### Cerebral Mitochondrial Metabolism

The primary analysis showed a statistically significant 24% increase in bihemispheric CMRO<sub>2</sub> in PD ( $p=.037$ ) (Table 1). This increase is the opposite direction expected for defects in mitochondrial electron transport. Bihemispheric CMRglc was increased by 15% and CMRO<sub>2</sub>/CMRglc was increased by 10%. Both of these changes are also in the opposite direction expected with defects in mitochondrial electron transport. Examination of the confidence intervals for the differences between the two groups for these latter two measurements demonstrates that there is less than a 6% chance that CMRglc is lower in PD by any amount and only a 10% chance that CMRglc/CMRO<sub>2</sub> is reduced by 10% or more.

Similar results, albeit with more measurement imprecision as expected, were found in the substantia nigra. Examination of the confidence intervals for the differences between the two groups demonstrates that there is less than a 20% chance that substantia nigra CMRO<sub>2</sub> in PD is lower by more than 10%, that CMRglc is lower by more than 16% and that there is only a 10% chance that CMRglc/CMRO<sub>2</sub> is reduced by any amount.

Measurements from putamen and globus pallidus also showed increases in regional CMRO<sub>2</sub> and CMRglc (Table 2). Analysis of regional/bihemispheric ratios showed no difference between controls and participants with PD indicating that the increases in regional metabolism were primarily a reflection of overall bihemispheric changes. There were no differences in CMRO<sub>2</sub> or CMRglc between the structures ipsilateral and contralateral to the side of the body with the greatest signs (data not shown).

Systemic physiological measurements were comparable between the participants with PD and the controls:  $p\text{CO}_2$   $36 \pm 4$  vs.  $37 \pm 3$  mm Hg ( $p=0.406$ ), arterial oxygen content  $17.3 \pm 1.4$  vs.  $17.0 \pm 1.5$  ml  $100\text{mL}^{-1}$  ( $p=0.604$ ) and arterial plasma glucose  $4.97 \pm 0.45$  vs.  $4.72 \pm 0.38$  micromoles  $\text{mL}^{-1}$  ( $p=.159$ ).

There were no differences in volume between the normal controls and the participants for substantia nigra ( $p=.109$ ), putamen ( $p=.465$ ) or globus pallidus ( $p=.966$ ).

## DISCUSSION

The CMRO<sub>2</sub> method that we have used has been validated for quantitative accuracy in non-human primates across a wide range of CMRO<sub>2</sub> (Mintun et al, 1984; Altman et al, 1991). Included in these validation studies were measurements during intra-aortic sodium cyanide infusion, specifically demonstrating the ability of this technique to accurately measure a reduction in CMRO<sub>2</sub> under conditions of reduced mitochondrial ETS activity (Altman et al, 1991).

We corrected for artifactual reductions in PET measurements due to partial volume effects from increases in ventricular, cisternal and sulcal CSF volume due to atrophy. The method does not correct for partial volume effects on the globus pallidus and putamen from surrounding white matter, which will worsen with atrophy of these structures (Videen et al, 1988; Videen et al, 1999). These white matter effects cause lower values for CMRO<sub>2</sub> and CMRglc when globus pallidus and putamen are smaller. However, we found no difference in the volume of these structures between normal controls and participants with PD so this cannot be the explanation for the increased metabolism in PD.

The hypothesis that patients with early PD have a defect in cerebral mitochondrial electron transport was tested by comparison of bihemispheric CMRO<sub>2</sub> between participants with PD and age-matched normal controls. This primary analysis showed a statistically significant 24% increase in bihemispheric CMRO<sub>2</sub> in PD. Explanatory analyses showed that CMRO<sub>2</sub>/CMRglc was not reduced. Similar results, albeit with more measurement imprecision as expected, were found in the substantia nigra. Increased CMRO<sub>2</sub> with a normal CMRO<sub>2</sub>/CMRglc is inconsistent with a defect in mitochondrial oxidative phosphorylation due to reduced activity of the mitochondrial ETS (Brierley et al, 1977; Frackowiak et al, 1988). Whereas a finding of normal CMRO<sub>2</sub> in PD would not exclude the possibility of dysfunction of mitochondrial ETS since complex I, III and IV activity can be substantially reduced before there is a reduction in CMRO<sub>2</sub>, dysfunction of the ETS cannot be the explanation for *increased* CMRO<sub>2</sub> in PD (Davey et al, 1998). Since PD symptoms were already manifest in these 12 patients, we can exclude deficient energy production due to a reduced activity of the mitochondrial ETS as a pathogenic mechanism of their disease. Thus, while defects in mitochondrial ETS may be present in some patients with PD, the absence of such defects in these 12 patients with early PD indicates that they cannot be essential to the pathogenesis of neuronal death in early PD.

Previous studies of CMRglc in PD have yielded mixed results. In five studies of global CMRglc, four have reported reductions of approximately 20% and one reported no significant difference compared to age-matched controls (Kuhl et al, 1984; Leenders et al, 1985; Eidelberg et al, 1993; Eidelberg et al, 1994; Piert et al, 1996). In one of these studies, reductions in global CMRglc were seen only after L-dopa was administered suggesting that the reduction in metabolism may be at least in part due to medication effects (Piert et al, 1996). Berding et al have suggested that hypometabolism parallels disease duration (Piert et al, 1996). Thus, these reported changes in CMRglc likely reflect a consequence of the PD disease process. We deliberately chose to study patients with very early disease to try to determine if there was metabolic dysfunction that caused PD. The mean disease duration of 22 months in our study was substantially shorter than in these previous studies where it ranged from 4 to 15 years. Our analysis using absolute and relative measurements showing a trend toward increased global CMRglc in very early PD supports the theory that the reported reductions in metabolism are a consequence, not a cause, of the disease.

Basal ganglia metabolism in PD has been reported to be increased, decreased or unchanged (Kuhl et al, 1984; Rougemont et al, 1984; Martin et al, 1984; Wolfson et al, 1985; Leenders et al, 1985; Mohr et al, 1992; Eidelberg et al, 1993; Eidelberg et al, 1994; Eidelberg et al, 1995;

Piert et al, 1996). In these studies, findings are dependent on whether analysis is performed using absolute values, relative values or more sophisticated image analysis techniques such as statistical parametric mapping or scaled subprofile modeling (Eidelberg et al, 1993; Eidelberg et al, 1995; Piert et al, 1996). Increased metabolism in basal ganglia structures has been ascribed to loss of dopaminergic inhibitory pathways (Martin et al, 1984; Wolfson et al, 1985; Eidelberg et al, 1993). Following unilateral 6-hydroxydopamine lesions of the substantia nigra in rats, glucose hypermetabolism is focally restricted to ipsilateral globus pallidus and is transient (Wooten and Collins 1981). We found no evidence that the increases in basal ganglia CMRO<sub>2</sub> and CMRglc were focal or related to the more clinically involved side, but we cannot exclude this possibility due to the small sample size and low power. Nevertheless, loss of inhibitory dopaminergic input seems an unlikely explanation for the general increase in hemispheric CMRO<sub>2</sub> that we measured. Alternatively, this general increase in CMRO<sub>2</sub> could be due, not to increased metabolic demand, but to an uncoupling of ATP production from oxidation in the terminal stage of oxidative phosphorylation. Uncoupling (dysfunction of Complex V ATP synthase) produces an increase in both CMRO<sub>2</sub> and CMRglc similar to what we observed (Patel and Brewer 2003; Tretter and Adam-Vizi 2007). Whether uncoupling of oxidative phosphorylation occurs in early PD and whether or not it is important in the pathogenesis of PD will require further study.

## ACKNOWLEDGMENTS

This research was supported by USPHS grants NS 41771 and NS35966, the Lillian Strauss Institute for Neuroscience and the Elliot Stein Family Fund of the Barnes-Jewish Hospital Foundation, the Huntington's Disease Society of America Center of Excellence at Washington University, the American Parkinson Disease Association (APDA) Advanced Center for Research at Washington University, and the Greater St. Louis Chapter of the APDA. We would like to thank Lennis Lich, John Hood, Susanne Fritsch and the Washington University Cyclotron Staff for their assistance.

## REFERENCES

1. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nat Rev Neurosci* 2006;7:207–219. [PubMed: 16495942]
2. Altman DI, Lich LL, Powers WJ. Brief inhalation method to measure cerebral oxygen extraction fraction with PET: Accuracy determination under pathologic conditions. *J Nucl Med* 1991;32:1738–1741. [PubMed: 1880576]
3. Astrup J, Sorensen PM, Sorensen HR. Oxygen and glucose consumption related to Na<sup>+</sup>-K<sup>+</sup> transport in canine brain. *Stroke* 1981;12:726–730. [PubMed: 7303061]
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003;24:197–211. [PubMed: 12498954]
5. Brierley JB, Prior PF, Calverley J, Brown AW. Cyanide intoxication in *Macaca mulatta*. Physiological and neuropathological aspects. *J Neurol Sci* 1977;31:133–157. [PubMed: 13159]
6. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. *Ann Neurol* 1992;32:S125–S127. [PubMed: 1510370]
7. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. *Brain* 1999;122(Pt 8):1421–1436. [PubMed: 10430829]
8. Davey GP, Peuchen S, Clark JB. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. *J Biol Chem* 1998 May 22;273:12753–12757. [PubMed: 9582300]
9. Diemel GA, Wang RY, Cruz NF. Generalized sensory stimulation of conscious rats increases labeling of oxidative pathways of glucose metabolism when the brain glucose-oxygen uptake ratio rises. *J Cereb Blood Flow Metab* 2002;22:1490–1502. [PubMed: 12468893]
10. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S. The metabolic topography of parkinsonism. *J Cereb Blood Flow Metab* 1994;14:783–801. [PubMed: 8063874]



11. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Belakhlef A, Mandel F, Przedborski S, Fahn S. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. *Neurology* 1995;45:1995–2004. [PubMed: 7501148]
12. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. *Ann Neurol* 1993;33:518–527. [PubMed: 8498828]
13. Foster ER, Black KJ, Antenor-Dorsey JA, Perlmutter JS, Hershey T. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. *Brain Cogn*. 2007
14. Frackowiak RSJ, Herold S, Petty RK, Morgan-Hughes JA. The cerebral metabolism of glucose of oxygen measured with positron tomography in patients with mitochondrial diseases. *Brain* 1988;111:1009–1024. [PubMed: 3263167]
15. Gottstein U, Bernsmeier A, Sedlmeyer I. Der Kohlenhydratstoffweehsel des menschlichen Gehirns bei Schlafmittelvergiftung. *Klin Wschr* 1963;41:943–948. [PubMed: 14103599]
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17:427–442. [PubMed: 6067254]
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992;55:181–184. [PubMed: 1564476]
18. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. *J Neurosci* 2006;26:5256–5264. [PubMed: 16687518]
19. Krigel D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. The Royal Kings and Queens Parkinson Disease Research Group. Platelet mitochondrial function in Parkinson's disease. *Ann Neurol* 1992;32:782–788. [PubMed: 1471869]
20. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. *Ann Neurol* 1984;15:419–424. [PubMed: 6610384]
21. Leenders KL, Wolfson L, Gibbs JM, Wise RJ, Causton R, Jones T, Legg NJ. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. *Brain* 1985;108:171–191. [PubMed: 3978397]
22. Martin WR, Beckman JH, Calne DB, Adam MJ, Harrop R, Rogers JG, Ruth TJ, Sayre CI, Pate BD. Cerebral glucose metabolism in Parkinson's disease. *Can J Neurol Sci* 1984;11:169–173. [PubMed: 6608981]
23. Martin WRW, Powers WJ, Raichle ME. Cerebral blood volume measured with inhaled C15O and positron emission tomography. *J Cereb Blood Flow Metab* 1987;7:421–426. [PubMed: 3497162]
24. Mintun MA, Raichle ME, Martin WRW, Herscovitch P. Brain oxygen utilization measured with O15 radiotracers and positron emission tomography. *J Nucl Med* 1984;25:177–187. [PubMed: 6610032]
25. Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Grimes JD, Chase TN. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. *Can J Neurol Sci* 1992;19:163–169. [PubMed: 1623440]
26. Patel JR, Brewer GJ. Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid. *J Neurosci Res* 2003;72:527–536. [PubMed: 12704814]
27. Phelps ME, Huang S-C, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurements of local cerebral glucose metabolic rate in humans with [F18]2-fluoro-2-deoxy-D-glucose: validation of method. *Ann Neurol* 1979;6:371–388. [PubMed: 117743]
28. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. *J Nucl Med* 1996;37:1115–1122. [PubMed: 8965180]
29. Powers WJ, Videen TO, Markham J, McGee-Minnich L, Antenor-Dorsey JV, Hershey T, Perlmutter JS. Selective defect of in vivo glycolysis in early Huntington's disease striatum. *Proc Natl Acad Sci U S A* 2007;104:2945–2949. [PubMed: 17299049]

30. Raichle ME, Martin WRW, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H<sub>2</sub><sup>15</sup>O. II. Implementation and validation. *J Nucl Med* 1983;24:790–798. [PubMed: 6604140]
31. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism--a prospective study. *Can J Neurol Sci* 1991;18:275–278. [PubMed: 1913360]
32. Rango M, Bonifati C, Bresolin N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. *J Cereb Blood Flow Metab* 2006;26:283–290. [PubMed: 16094320]
33. Rougemont D, Baron JC, Collard P, Bustany P, Comar D, Agid Y. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1984;47:824–830. [PubMed: 6332176]
34. Schapira AH. Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal. *Mov Disord* 1994;9:125–138. [PubMed: 8196673]
35. Tretter L, Adam-Vizi V. Uncoupling is without an effect on the production of reactive oxygen species by in situ synaptic mitochondria. *J Neurochem* 2007;103:1864–1871. [PubMed: 17854347]
36. Videen TO, Dunford-Shore JE, Diringner MN, Powers WJ. Correction for partial volume effects in regional blood flow measurements adjacent to hematomas in humans with intracerebral hemorrhage: Implementation and validation. *J Comput Asst Tomogr* 1999;23:248–256.
37. Videen TO, Perlmutter JS, Herscovitch P, Raichle ME. Brain blood volume, blood flow, and oxygen utilization measured with O-15 radiotracers and positron emission tomography: revised metabolic computations. *J Cereb Blood Flow Metab* 1987;7:513–516. [PubMed: 3497165]
38. Videen TO, Perlmutter JS, Mintun MA, Raichle ME. Regional correction of positron emission tomography data for the effects of cerebral atrophy. *J Cereb Blood Flow Metab* 1988;8:662–670. [PubMed: 3262114]
39. Wolfson LI, Leenders KL, Brown LL, Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. *Neurology* 1985;35:1399–1405. [PubMed: 4033924]
40. Woods RP, Mazziota JC, Cherry SR. MRI-PET registration with automated algorithm. *J Comput Assist Tomogr* 1993;17:536–546. [PubMed: 8331222]
41. Wooten GF, Collins RC. Metabolic effects of unilateral lesion of the substantia nigra. *J Neurosci* 1981;1:285–291. [PubMed: 7264720]

**Table 1**  
 Bilateral Cerebral and Substantia Nigra Metabolism in Early Parkinson Disease

	Number	CMRO2	CMRglc	CMRO2/CMRglc
<b>Hemispheric</b>				
Normal Controls	12	115 ± 25	20.7 ± 2.6	5.6 ± 1.3
Parkinson Disease	12	143 ± 36	23.8 ± 4.4	6.15 ± 1.6
t-test		p=.037*	p=.056	p=.39
<b>Substantia Nigra</b>				
Normal Controls	10	110 ± 71	15.9 ± 2.3	6.78 ± 3.91
Parkinson Disease	10	147 ± 91	17.9 ± 3.2	8.36 ± 4.91
t-test		p=.313	p=.122	p=.437

\* Primary analysis

CMRO2 - cerebral metabolic rate of oxygen ( $\text{micromoles } 100\text{g}^{-1} \text{ min}^{-1}$ ), CMRglc – cerebral metabolic rate of glucose ( $\text{micromoles } 100\text{g}^{-1} \text{ min}^{-1}$ ), Values are mean ± SD.

Table 2

## Bilateral Basal Ganglia Metabolism in Early Parkinson Disease

	Number	CMRO2	Regional/Hemispheric CMRO2 Ratio	CMRglc	Regional/Hemispheric CMRglc Ratio
Putamen					
Normal Controls	12	138 ± 27	1.21 ± 0.06	24.2 ± 4.1	1.17 ± 0.13
Parkinson Disease	12	175 ± 40	1.23 ± 0.19	29.8 ± 5.0	1.26 ± 0.11
t-test		p=.016	p=.86	p=.007	p=.08
Globus Pallidus					
Normal Controls	12	110 ± 39	0.95 ± 0.19	16.8 ± 2.8	0.81 ± 0.07
Parkinson Disease	12	137 ± 37	0.98 ± 0.23	20.6 ± 2.8	0.88 ± 0.12
t-test		p=.097	p=.702	p=.003	p=.093

CMRO2 - cerebral metabolic rate of oxygen (micromoles 100g<sup>-1</sup> min<sup>-1</sup>), CMRglc - cerebral metabolic rate of glucose (micromoles 100g<sup>-1</sup> min<sup>-1</sup>), Values are mean ± SD.